Solving AAV’s one-and-done problem: ASGCT highlights

Solving AAV’s redosing problem could change the economics of rare disease gene therapy and reignite industry interest in a modality that has fallen out of favor. The concept, a hot topic at this week’s ASGCT conference, is creeping closer to reality.

The 2026 American Society of Gene & Cell Therapy (ASGCT) meeting will feature at least 12 preclinical presentations that describe strategies to enable repeat dosing or overcome pre-existing immunity to AAV vectors...